Valuation: Magenta Therapeutics

Capitalization 42.24M 35.93M 33.3M 31.12M 58.01M 3.88B 61.49M 381M 151M 1.83B 158M 155M 6.67B P/E ratio 2021
-3.42x
P/E ratio 2022 -0.31x
Enterprise value -39.84M -33.88M -31.4M -29.35M -54.71M -3.66B -57.98M -359M -142M -1.73B -149M -146M -6.29B EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
-
Yield 2021 *
-
Yield 2022 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.82%
Current month+367.50%
Current year+367.50%
More quotes
3 years 5.89
Extreme 5.888
53.79
5 years 5.14
Extreme 5.136
227.2
10 years 5.14
Extreme 5.136
336
More quotes

Financials

2021 2022
Net sales - -
Net income -71.14M -60.5M -56.08M -52.4M -97.69M -6.54B -104M -641M -254M -3.09B -267M -261M -11.22B -76.46M -65.03M -60.28M -56.33M -105M -7.03B -111M -689M -273M -3.32B -287M -281M -12.07B
Net Debt -177M -150M -139M -130M -243M -16.26B -258M -1.59B -633M -7.67B -663M -650M -27.92B -82.08M -69.81M -64.71M -60.47M -113M -7.54B -119M -739M -294M -3.56B -308M -301M -12.95B
More financial data * Estimated data
Logo Magenta Therapeutics
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Employees
67
Sector
-
More about the company
Date Price Change Volume
26-01-23 52.33 $ -0.82% 989,864
26-01-22 52.76 $ +9.85% 1,445,402
26-01-21 48.03 $ +3.07% 743,115
26-01-20 46.60 $ +5.67% 1,021,737
26-01-16 44.10 $ +0.23% 638,640

Delayed Quote Nasdaq, January 23, 2026 at 04:00 pm EST

More quotes